Lactobacillus paracasei Jlus66 ameliorates hyperuricemia by inhibiting xanthine oxidase activity, modulating uric acid transporter proteins and the gut microbiota

A novel strain of Lactobacillus paracasei Jlus66 was isolated from a traditional fermented dairy product known as "Nai Geda", and its role in hyperuricemia remains unclear. We constructed a mouse model using potassium oxonate and a high-purine diet to examine the impacts of Jlus66 supplementation on the performance of hyperuricemia in vivo. The results revealed that Lactobacillus paracasei Jlus66 intervention substantially lowered blood uric acid concentrations through suppressing xanthine oxidase activity in the liver to reduce uric acid synthesis and modulating uric acid transport to enhance its renal excretion. Furthermore, Lactobacillus paracasei Jlus66 supplementation increased short-chain fatty acids in cecal samples, which might account for the reduced secretion of serum pro-inflammatory cytokines IL-6, IL-1β, and TNF-α. Lactobacillus paracasei Jlus66 enhanced intestinal barrier function through upregulating tight junction proteins and reinstating gut microbiota homeostasis. In conclusion, Lactobacillus paracasei Jlus66 can be a potential probiotic in the administration of hyperuricemia through modulating gut microbiota, promoting uric acid excretion, and inhibiting uric acid synthesis.